Japan Biosimilars - ¥200b Worth of Biologic Products Going Off Patent by 2015

MUMBAI, India, February 12, 2013 /PRNewswire/ --

Bharat Book Bureau has announces the release of its latest report - Therapeutic Class Report Overview - Japan Biosimilars

(http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/therapeutic-class-report-overview-japan-biosimilars.html)

Abstract

¥200b worth of biologic products is going off patent by 2015 and this value exceeds ¥500b if we include products that will see their patent expiries by 2021 in Japan. There are a number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story of generic - preliminary because the much higher cost of biologic therapy brings significant burden on patients despite relatively low co-pay in Japan - and this will push individuals and DPC Hospitals to use biogeneric products to a greater extent unlike generic drugs. Secondly, the regulatory supports are going to be stringent enough to ensure quality measures and leave no room for imported products, thus eliminating the 'not made in Japan' factor from prescribers' and users' mindsets.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

Anticipating this opportunity and favorable macro forces as compared to generics, a number of companies aim to exploit this - Japan has seen a flood like consolidation and partnering activities in biosimilar space. While a dozen+ companies have already laid their road map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan.

In this piece, we attempt to evaluate the future competitive landscape of the biosimilars space in Japan, assess the overall attractiveness of the same, and try to identify the key determinates to succeed in this space.

Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=371870

Table of Contents

Investment Thesis
Opening biosimilar opportunity in Japan in next decade
Key local players
Consolidation trend in biogeneric space
Expected market penetration - Does it will repeat the lethargic growth story of small molecule generics in Japan?

Evolving Biogeneric landscape in Japan
Launched biogenerics in Japan and their uptake trend
Top 10 small molecules vs. Top 10 biologics in Japan
Likely launch schedule of select biosimilars

Japan Specific Hurdles & Drivers
Biogeneric opportunity, it's likely profitability vs. risk profile
Development cost of biosimilars vs. small molecules
Price difference vs. small molecules and DPC hospitals business are key drivers
-Co-pay Slabs in Japan
-Saving through biosimilar use
-Pricing of key biologics in Japan

Regulatory Guidelines: Stringent Enough to Restrict Scope of Import
Korosho guidelines- Key difference vs. US, EU
JP requirement of
-Reference Product
-Interchangeability/Substitution
-Pharmacovigilance
-PMS for biosimilar

Select Japanese Companies venturing into biogeneric space - Their strategy and Pipeline

JCR Pharmaceuticals

Meiji Seika Pharma

Fuji Film Kyowa Kirin Biologics

Nichi Iko

Mochida

Nipro Pharma

Yoshindo

Nippon Kayaku

Sawai

Towa

Daiichi Sankyo

UMN Pharma

Kissei

Kyowa Hakko Kirin

Toyobo Biologics

Annexure-I - Consolidation Activities in Biosimilar Space in Japan

Annexure-II - Biosimilar Guidelines adopted by various countries

Get an overview of the report at or request for sample pages at -

http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/therapeutic-class-report-overview-japan-biosimilars.html

Complete range of reports on Therapeutic Class: http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Therapeutic+Class+Report&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik

For Complete range of Related Reports:

• Biosimilars  - http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Biosimilars&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik
  
• Drugs/Medicines - http://www.bharatbook.com/market-research-report/Drugs-Medicines.html
  
• Vaccines - http://www.bharatbook.com/market-research-report/Vaccines.html
  
• Antibodies - http://www.bharatbook.com/searchResults.asp?srchtype=qik&Keywords=&Title=antibod&Publisher=&PublishPeriod=&PubfrmDate=&PubToDate=&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&sortby=dd&RS=&iCurpage=1
  
• Biotechnology - http://www.bharatbook.com/market-research-report/Biotechnology.html
  
• Drug Delivery - http://www.bharatbook.com/market-research-report/Drug-Delivery.html

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Maria
Bharat Book Bureau
India : +91-22-27810772, 27810773
USA/Canada - 1-866-279-8368 (Toll free)
Skype - bharatbook
E-mail : maria@bharatbook.com
Website : http://www.bharatbook.com

SOURCE Bharat Book Bureau